Tag Archives: Treatment

More weight gain in people starting HIV treatment with newer integrase inhibitors or darunavir

A US study has concluded that weight gain is greater by around 2 to 4 kg in HIV-positive people taking bictegravir or dolutegravir as part of their first antiretroviral therapy (ART), compared to their counterparts using other drug regimens. A similar effect was reported in those using the protease inhibitor darunavir. The study led by… Read More »

Drug being tested for at-home treatment in hopes of slowing virus

Researchers at Beth Israel Deaconess Medical Center are testing a new approach to fighting COVID-19, using a repurposed antiviral AIDS drug for at-home treatment during the first days of symptoms in hopes of slowing the virus early and heading off hospitalization, intensive care, and death. The nationwide clinical trial is being led by Nathan Shapiro,… Read More »

FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Print this page PLANEGG/MUNICH, Germany – August 1, 2020 and WILMINGTON, Del. – July 31, 2020 MorphoSys AG NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi… Read More »

Coronavirus vaccine: Treatment approved for use by NHS – ‘Thousands of lives to be saved’

Coronavirus has killed more than 40,000 people in the UK, with the number continuing to rise. But, scientists have made a breakthrough in the search for a COVID-19 vaccine. The NHS has been backed to immediately use the dexamethasone steroid as a treatment for coronavirus. The drug has been revealed to lower the risk of… Read More »

FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy

Print this page April 8, 2020 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior… Read More »